A Case of Lung Adenocarcinoma Harboring a Rare LOC285000-ALK-NCK2 Gene Fusion Identified by Next-Generation Sequencing With Long-Term Response to Crizotinib

A Case of Lung Adenocarcinoma Harboring a Rare LOC285000-ALK-NCK2 Gene Fusion Identified by Next-Generation Sequencing With Long-Term Response to Crizotinib

Most patients with NSCLC, initially sensitive, will develop resistance after a period of time after the application of ALK inhibitors. We present here a rare LOC285000-ALK-NCK2 gene fusion with response to crizotinib treatment; the patient achieved a progression-free survival of 23 months.

Bibliographic Details
Main Authors: Min Zhang, MBBS, Huan Zhou, MM, Dan Liu, MD, PhD, Ruoying Yu, MD, PhD, Jun Chen, MD, PhD
Format: Article
Language:English
Published: Elsevier 2021-02-01
Series:JTO Clinical and Research Reports
Subjects:
Lung cancer
ALK gene
Crizotinib
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364320301521

Internet

http://www.sciencedirect.com/science/article/pii/S2666364320301521

Similar Items